dihexa autism D I H E X A is having a moment right now… and I get why. When something gets labeled as “brain repair” or “synapse growth,” it spreads FAST especially in communities dihexa autism Study Finds Three-Supplement

Quick Comparison Feature CagriSema Retatrutide Development owner Novo Nordisk Eli Lilly Core strategy Combination therapy Single-molecule multi-agonist Pathways Amylin + GLP-1 GIP + GLP-1 + glucagon Main components Cagrilintide + semaglutide Retatrutide (LY3437943) 2026 status Phase 3 / regulatory-watch candidate Phase 3 TRIUMPH program Best-fit research question Can amylin extend GLP-1 results

Peer review Peer review information Nature Metabolism thanks the anonymous reviewers for their contribution to the peer review of this work

CagriSema: 23.0% at 84 weeks vs tirzepatide 15 mg: 25.5%

If you see particles floating in solution after mixing, the peptide has degraded or precipitated

Mapping each compound to its actual research context prevents the most common category error treating them as interchangeable fat-loss shots. The table below shows that they anchor to different indications and different evidence tiers